# PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease

> **NCT00455546** · PHASE2 · COMPLETED · sponsor: **Anthera Pharmaceuticals** · enrollment: 400 (actual)

## Conditions studied

- Coronary Artery Disease (CAD)

## Interventions

- **DRUG:** A-002

## Key facts

- **NCT ID:** NCT00455546
- **Lead sponsor:** Anthera Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2010-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00455546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00455546, "PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00455546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*